The CDM Insights software, which can be utilized with scans from 1.5T and 3T MRI, reportedly provides new measurements of cortical thickness and brain microstructure.
The Food and Drug Administration (FDA) has granted 510(k) clearance for CDM Insights, a magnetic resonance imaging (MRI)-based software that may facilitate early detection of neurodegeneration.
The cloud-native CDM (Cortical Disarray Measurement) Insights software enables neuroradiologists to assess new measurements of brain microstructure and cortical thickness that were previously unavailable in the United States, according to Oxford Brian Diagnostics, the developer of the CDM Insights software.
For the assessment of brain MRI, the newly FDA-cleared CDM Insights software provides neuroradiologists with new measurements of brain microstructure and cortical thickness that were previously unavailable in the United States, according to Oxford Brain Diagnostics, the developer of CDM Insights. (Image courtesy of Adobe Stock.)
"Our technology empowers clinicians with the tools they need to detect subtle brain changes and to diagnose with confidence at an early stage,” noted Steven Chance, Ph.D., the CEO and co-founder of Oxford Brian Diagnostics. “These insights also help patients gain a better understanding of the changes happening in their brains, addressing the uncertainty often experienced with the early signs of Alzheimer's disease. Ultimately, this enables providers … to understand patient brain structure changes prior to symptom progression and improve patient outcomes."
The company said CDM Insights allows clinicians to monitor brain changes across multiple stages of adult life and enables assessment of patients with neurodegenerative disorders such as Alzheimer’s disease. The software can be utilized with scans from 1.5T or 3T MRI devices, according to Oxford Brain Diagnostics.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.